Cardiovascular Events Based On Statin Initiation In The Elderly

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

31603 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-11-30

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare rates and risk of primary cardiovascular events among elderly patients newly initiating therapy with atorvastatin or simvastatin. The specific objectives for this project are to: 1) examine the demographic and clinical characteristics of the elderly patients in whom atorvastatin or simvastatin was newly initiated; and 2) compare cardiovascular event rates in elderly patients in whom atorvastatin or simvastatin was newly initiated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease

NCT00134264

Coronary Disease Diabetes Mellitus

TERMINATED PHASE3

Atorvastatin For The Reduction Of Ventricular Arrhythmias

NCT00457340

Arrhythmia

COMPLETED PHASE4

Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD

NCT00159835

Cardiovascular Diseases

COMPLETED PHASE4

Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients

NCT01013103

Coronary Artery Disease HMG-CoA Reductase Inhibitor Toxicity Atherosclerosis +2 more

COMPLETED PHASE4

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

NCT00134173

Coronary Disease Coronary Arteriosclerosis Hyperlipidemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All subjects meeting sample definition, all inclusion criteria, and none of the exclusion criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atorvastatin Initiators

Intervention Type OTHER

Retrospective database analysis no intervention performed.

Simvastatin Initiators

Intervention Type OTHER

Retrospective database analysis no intervention performed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin Initiators

Retrospective database analysis no intervention performed.

Intervention Type OTHER

Simvastatin Initiators

Retrospective database analysis no intervention performed.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 1 fill for atorvastatin or simvastatin (not including combination therapy) between 01 July 2006 and 30 November 2008
* Age ≥ 65 years as of the year of index date
* Continuous enrollment with medical and pharmacy benefits during the analytic period

Exclusion Criteria

* 1 or more fills for a statin or other dyslipidemia medication in the 12-month pre-index period
* A pharmacy fill for clopidogrel or nitrates (except concomitant hydralazine) in the 12-month pre-index period
* Patients with evidence of a cardiovascular event in the 12-month pre-index period.
* Patients who received both atorvastatin and simvastatin on the index date
* Patients with unknown gender or region
* Patients who received dyslipidemia medications other than the index drug within 1 months (30 days) following the index date

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No